A Phase IV, Open-Label, Single-Center, Prospective, Observational, 20-Year Follow-Up Study Assessing Long-Term Persistence Of Protective Antibody Levels Against The Hepatitis A virus (HAV) In Healthy Volunteers Vaccinated With 2 Doses Of Inactivated Hepatitis A Vaccine (Epaxal) between 1992 and 1995.
Phase of Trial: Phase IV
Latest Information Update: 06 Apr 2017
At a glance
- Drugs Hepatitis A vaccine inactivated (Primary)
- Indications Hepatitis A
- Focus Pharmacodynamics
- 06 Apr 2017 New trial record
- 09 Feb 2017 Results published in the Vaccine Journal.